Document is current

Article History

Accepted: 11 September 2024

First Online: 21 October 2024

Declarations

:

: This study was funded by the ACTION Study Group.

: Michel Zeitouni has received research grants and honorarium from Bayer, BMS Pfizer, la Fédération Française de Cardiologie, Servier, AstraZeneca, NovoNordisk, and Abbott. Johanne Silvain has received research grants and honorarium from AstraZeneca, Bayer HealthCare SAS, Abbott Medical France SAS, Biotronik, Boehringer Ingelheim France, CSL Behring SA, Gilead Science, and Sanofi-Aventis France; and is a stockholder of Pharmaseeds, Terumo France SAS, and Zoll. Gilles Montalescot has received research grants and honorarium from Abbott, Amgen, AstraZeneca, Ascendia, Bayer, BMS, Boehringer-Ingelheim, BostonScientific, Celecor, CSL Behring, Idorsia, Lilly, Novartis, Novo, Opalia, Pfizer, Quantum Genomics, Sanofi, and Terumo; and is an Editorial Board member of the American Journal of Cardiovascular Drugs but was not involved in the selection of peer reviewers for this manuscript nor any of the subsequent editorial decisions. Elodie Dorvillius, David Sulman, Niki Procopi, Frederic Beaupré, Perrine Devos, Olivier Barthélémy, Stéphanie Rouanet, Arnaud Ferrante, Juliette Chommoeloux, Guillaume Hekimian, and Mathieu Kerneis have no conflicts of interest to declare that may be relevant to the contents of this study.

: MZ, JS, GM: Supervision, validation, visualization, writing, reviewing and editing, funding, methodology. ED, DS, NP, FB, PD, OB, AF, JC, GH, MK: Conceptualization, data curation, investigation, writing, reviewing, editing. SR: Statistician, methodology, project administration software, validation

: The datasets analyzed during the current study are available from the corresponding author, Michel Zeitouni, upon reasonable request. Access will be granted following appropriate review and approval.

: This analysis was undertaken in participants from the ACTION-SHOCK registry that was approved by the Ethics Committee of Sorbonne Université, Paris, France (CER-2022-047).

: Not applicable.

: An information letter was sent to all patients matching the selection criteria stating their right to decline participation. In the absence of refusal, the patient was included in the study.

: Not applicable.